Keywords: مهار کننده های آراماتاز; Aromatase inhibitors; Breast cancer; Medicinal chemistry; Molecular modeling; Ring substituted androstanes; Steroids;
مقالات ISI مهار کننده های آراماتاز (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده های آراماتاز; Breast cancer; Osteoporosis; Fractures; Aromatase inhibitors; Screening; Bisphosphonates; Denosumab;
Keywords: مهار کننده های آراماتاز; Endometrial carcinoma; Therapy; Aromatase; Aromatase inhibitors; Estrogen
Keywords: مهار کننده های آراماتاز; Aromatase inhibitors; Bone mineral density; Osteoporotic fracture; Specific osteoporosis treatment; Breast cancer
Keywords: مهار کننده های آراماتاز; Breast Neoplasms; Aromatase Inhibitors; Testosterone; Sexual Dysfunction; Quality of Life
Keywords: مهار کننده های آراماتاز; Adherence; Aromatase inhibitors; Tamoxifen; Toxicity; Trastuzumab;
Keywords: مهار کننده های آراماتاز; Acupuncture; Breast neoplasm; Clinical trial; Aromatase inhibitors; Adverse effects; Musculoskeletal; Joint pain;
Keywords: مهار کننده های آراماتاز; Aromatase inhibitors; Bisphosphonates; Bone loss; Early breast cancer; Postmenopausal;
Keywords: مهار کننده های آراماتاز; Breast cancer; pain; estrogen deprivation; aromatase inhibitors; arthritis;
Keywords: مهار کننده های آراماتاز; Late-Onset Hypogonadism; Testosterone Deficiency; Aromatase Inhibitors; Testosteroneâ:âEstradiol Ratio; T/E2 Ratio; Low Testosterone;
Keywords: مهار کننده های آراماتاز; Breast cancer; Chemotherapy-induced amenorrhea; Chemotherapy-induced menopause; Aromatase inhibitors; Ovarian reserve;
Keywords: مهار کننده های آراماتاز; osteoporosis; secondary osteoporosis; fragility fractures; hyperparathyroidism; glucocorticoids; multiple myeloma; vitamin D deficiency; aromatase inhibitors; hyperthyroidism; hypercalciuria
Keywords: مهار کننده های آراماتاز; Aromatase inhibitors; Premenopausal patients; Breast cancer;
Keywords: مهار کننده های آراماتاز; Postmenopausal; Breast cancer; Aromatase inhibitors;
Keywords: مهار کننده های آراماتاز; Arthralgia; breast cancer; joint pain; survey; tamoxifen; aromatase inhibitors;
Keywords: مهار کننده های آراماتاز; Antiestrogens; Aromatase inhibitors; Hormone dependent cancers; 17β-Hydroxysteroids dehydrogenase inhibitors; Steroid conjugates; Steroid sulfatase inhibitors;
Keywords: مهار کننده های آراماتاز; Breast cancer; Persistence; Tamoxifen; Aromatase inhibitors
Keywords: مهار کننده های آراماتاز; Endocrine therapy; breast cancer; aromatase inhibitors; tamoxifen
Pulmonary benign metastasizing leiomyoma: A case report
Keywords: مهار کننده های آراماتاز; Benign metastasizing leiomyoma; Pulmonary metastasis; Aromatase inhibitors;
Place des nouveaux traitements médicaux dans l'endométriose douloureuse, RPC Endométriose CNGOF-HAS
Keywords: مهار کننده های آراماتاز; Endométriose; Traitement médical; Diénogest; Agonistes de la GnRH; Inhibiteurs de l'aromatase; Modulateurs des récepteurs sélectifs de l'estrogène; Modulateurs des récepteurs sélectifs de la progestérone; Anti-TNF alpha; Inhibiteurs des méta
Effects of the Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: A randomized, controlled clinical trial
Keywords: مهار کننده های آراماتاز; Breast cancer; Aromatase inhibitor; Musculoskeletal symptoms; Traditional Chinese Medicine; AEs; adverse events; AIs; aromatase inhibitors; AIMSS; aromatase inhibitor-associated musculoskeletal symptoms; ALT; alanine aminotransferase; BMD; bone mineral de
Neoadjuvant Endocrine Therapy
Keywords: مهار کننده های آراماتاز; Neoadjuvant endocrine therapy; Estrogen receptor-positive breast cancer; Neoadjuvant chemotherapy; Aromatase inhibitors;
Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance
Keywords: مهار کننده های آراماتاز; AIs; aromatase inhibitors; AO; acridine orange; AVOs; acid vesicular organelles; AKT; protein kinase B; CCCP; carbonyl cyanide m-chlorophenylhydrazone; CFBS; pre-treated charcoal heat-inactivated fetal bovine serum; DCFH2-DA; 2â²,7â²-dichlorodihydrofluo
Integrated in silico-in vitro strategy for screening of some traditional Egyptian plants for human aromatase inhibitors
Keywords: مهار کننده های آراماتاز; Aromatase inhibitors; Traditional Egyptian plants; Docking; Pharmacophore modelling; Structure-based and ligand-based virtual screening;
Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors
Keywords: مهار کننده های آراماتاز; Breast cancer; Aromatase inhibitors; Bone health; Vitamin D; Calcium;
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers
Keywords: مهار کننده های آراماتاز; Ovarian cancer; Everolimus; Aromatase inhibitors; PDX models;
Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04)
Keywords: مهار کننده های آراماتاز; Breast cancer; Adverse events; Aromatase inhibitors; Hot flushes;
Extended adjuvant endocrine therapy - A standard to all or some?
Keywords: مهار کننده های آراماتاز; ER-positive early breast cancer; Risk of relapse; Extended endocrine therapy; Tamoxifen; Aromatase inhibitors; Gene-expression profiles;
Impact of adjuvant anti-estrogen therapies (tamoxifen and aromatase inhibitors) on perioperative outcomes of breast reconstruction
Keywords: مهار کننده های آراماتاز; Adjuvant hormone therapy; Tamoxifen; Aromatase inhibitors; Wound healing; Breast reconstruction;
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer
Keywords: مهار کننده های آراماتاز; miRNA; Tamoxifen; Serum; Biomarkers; Breast cancer; 4-OHT; 4-hydroxytamoxifen; AI; aromatase inhibitors; E2; estradiol; EMT; epithelial-to-mesenchymal transition; ERE; estrogen response element; EGFR; epidermal growth factor receptor; ER; estrogen recepto
Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells
Keywords: مهار کننده های آراماتاز; AIs; aromatase inhibitors; CFBS; pre-treated charcoal heat-inactivated fetal bovine serum; CDX; casodex bicalutamide; DCFH2-DA; 2â²,7â²-dichlorodihydrofluorescein diacetate; DMEM; Dulbecco's Modified Eagle's Medium; E2; estradiol; ER; estrogen receptor;
Osteoporosis management in patients with breast cancer: EMAS position statement
Keywords: مهار کننده های آراماتاز; Breast cancer; Osteoporosis; Fractures; Screening; Aromatase inhibitors; Bisphosphonates; Denosumab; Adjuvant therapy;
Effect of sildenafil on human aromatase activity: From in vitro structural analysis to catalysis and inhibition in cells
Keywords: مهار کننده های آراماتاز; Aromatase inhibitors; Sildenafil; Cytochromes P450; Estrogens; Breast cancer;
Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study
Keywords: مهار کننده های آراماتاز; Breast cancer; Aromatase inhibitors; Vertebral fractures; Dual energy X-ray absorptiometry; Vertebral morphometry;
Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study
Keywords: مهار کننده های آراماتاز; BC; breast cancer; Tam; tamoxifen; AEBS; antiestrogen binding site; ET; endocrine therapy; OS; oxysterol; AI; aromatase inhibitors; 24-HC; 24-hydroxycholesterol; 25-HC; 25-hydroxycholesterol; 27-HC; 27-hydroxycholesterol; 7α-HC; 7α-hydroxycholesterol; 7
Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial
Keywords: مهار کننده های آراماتاز; TBS; Clinical trials; Aromatase inhibitors;
New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17
Keywords: مهار کننده های آراماتاز; Breast cancer; Letrozole; Vasomotor symptoms; Musculoskeletal symptoms; Aromatase inhibitors; Extended hormonal therapy;
Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons
Keywords: مهار کننده های آراماتاز; Breast cancer; Aromatase inhibitors; Chemotherapy; Bone health; Osteoporosis;
TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort
Keywords: مهار کننده های آراماتاز; Trabecular Bone Score; Aromatase inhibitors; Oral bisphosphonates; Bone mineral density; Tamoxifen; Breast cancer;
Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
Keywords: مهار کننده های آراماتاز; Breast cancer; Neoadjuvant treatment; Tamoxifen; Aromatase inhibitors; Fulvestrant; Oestrogen receptor positive
Synthesis and aromatase inhibitory evaluation of 4-N-nitrophenyl substituted amino-4H-1,2,4-triazole derivatives
Keywords: مهار کننده های آراماتاز; NKVMADUKKQVLFZ-UHFFFAOYSA-N; ABCAGXYFNPKNRK-UHFFFAOYSA-N; WEEKLVCMWOEOEO-UHFFFAOYSA-N; VYLXATYHRBWVGM-UHFFFAOYSA-N; CXRKTLMZZSGIMW-UHFFFAOYSA-N; VTKWHLTVQFICHN-UHFFFAOYSA-N; CFUZAKYLWMZPTP-UHFFFAOYSA-N; YFUZAMRGRLYSPI-UHFFFAOYSA-N; SVOHWISBUPWPGM-UHFFFAOY
LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome
Keywords: مهار کننده های آراماتاز; PIK3CA mutations; Breast cancer; First line aromatase inhibitors therapy; LRG1; AI; aromatase inhibitors; AKT; also known as Protein kinase B (PKB); BC; breast cancer; ER; estrogen receptor; FAM81B; family with sequence similarity, 81 member B; HER2; huma
Unravelling exemestane: From biology to clinical prospects
Keywords: مهار کننده های آراماتاز; AI(s); aromatase inhibitor (s); AKT; protein kinase B; AREG; amphiregulin; BMD; bone mineral density; CYP; cytochrome P450; DHEAS; dehydroepiandrosterone sulfate; EGF; epidermal growth factor; EGFR; epidermal growth factor receptor; EMA; European Medicine
Dry eyes and AIs: If you don't ask you won't find out
Keywords: مهار کننده های آراماتاز; Aromatase inhibitors; Breast cancer; Dry eyes;
Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane
Keywords: مهار کننده های آراماتاز; Estrogen receptor-positive breast cancer; Aromatase inhibitors; Exemestane metabolites; Apoptosis; Autophagy; Acquired-resistance; AIs; aromatase inhibitors; AO; acridine orange; AVOs; acid vesicular organelles; CCCP; carbonyl cyanide m-chlorophenylhydraz
Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics
Keywords: مهار کننده های آراماتاز; Unexplained infertility; aromatase inhibitors; letrozole; gonadotropins; clomiphene citrate; multiple gestations;
Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens
Keywords: مهار کننده های آراماتاز; LBD; ligand-binding domain; ERα; estrogen receptor α; NGS; next generation sequencing; ER+; ER-positive; AIs; aromatase inhibitors; MBC; metastatic breast cancer; ddPCR; droplet digital polymerase chain reaction; FFPE; formalin-fixed paraffin embedded;
Evaluación de la densidad mineral ósea en la monitorización de los efectos del tratamiento de cáncer de mama con inhibidores de la aromatasa: la importancia del cambio mÃnimo significativo
Keywords: مهار کننده های آراماتاز; Cáncer de mama; Inhibidores de la aromatasa; Resorción ósea; Densidad mineral ósea; AbsorciometrÃa de energÃa dual de rayos X; Cambio mÃnimo significativo; Breast cancer; Aromatase inhibitors; Bone loss; Bone mineral density; Dual energy absorptio
Laboratory-Clinic InterfaceIs the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?
Keywords: مهار کننده های آراماتاز; AI; aromatase inhibitors; BC; breast cancer; BCS; breast-conserving surgery; BCS; breast cancer survival; CAF; cyclophosphamide, doxorubicin and fluorouracil; CR; complete response; DFS; disease free survival; ER; oestrogen receptor; ET; endocrine therapy
Large-scale QSAR study of aromatase inhibitors using SMILES-based descriptors
Keywords: مهار کننده های آراماتاز; Aromatase inhibitors; Breast cancer; QSAR; SMILES; CORAL software; Data mining